The NIH said that while the anti-malarial drug did not cause harm to patients in the study, testing showed little evidence that it would benefit patients hospitalized with COVID-19.
Dr. Francis Collins says some candidates for a coronavirus vaccine will be ready to start large-scale human trials as early as next month. Scaling up production may start before tests are complete.
The project, run by the nonprofit EcoHealth Alliance, aimed to identify places to monitor, come up with strategies to prevent spillover of the virus and get a jump on creating vaccines and treatments.
The group of experts, assembled under the agency run by Dr. Anthony Fauci, warns that using a combination of hydroxychloroquine and azithromycin could result in potential toxicities.
Federal agencies and 16 big pharma companies will collaborate on drugs and vaccines, says Dr. Francis Collins, head of the National Institutes of Health.
New Yorker writer Michael Specter covered Fauci's early work in the AIDS epidemic. "He's always taken an open-minded approach to the problems," Specter says of the infectious-disease expert.
There are lots of questions about the novel coronavirus that we try to answer, including whether we should wear masks, if the U.S. is testing enough and if there's a drug that can treat COVID-19.
NPR tells the exclusive, behind-the-scenes story of the first person with a genetic disorder to be treated in the United States with the revolutionary gene-editing technique CRISPR.
Black scientists more often seek grants for community health studies, but molecular-level research proposals win more funding. More diversity throughout the process could help close the gap, says NIH.
During the 1980s and early 1990s, Rep. John Dingell was instrumental in expanding the Medicaid program, reshaping Medicare and modernizing the Food and Drug Administration. He died Thursday night.
After trying one treatment after another for his leukemia, 20-year old Aaron Reid enrolled in a study to test an experimental therapy using modified cells from his own body.
Researchers are working on better ways to teach patients' immune systems to root out and kill malignant cells. A promising approach involves cells that attack cancer two ways at one time.
Scientists and National Institutes of Health officials met with alcohol company executives and appeared to solicit money from them in violation of government policy. The NIH canceled the study.
Public health interventions and antiviral drugs have put HIV on the ropes in the U.S. But it's unlikely that infections can be wiped out without a vaccine.
The Senate agreement is now before the House, which needs to act by midnight to avert a shutdown. The deal appears to include almost every health priority Democrats have been pushing in recent months.
Federal researchers are collecting blood samples from 1 million Americans as part of an effort called "precision medicine." But some critics worry that the path ahead is expensive and unclear.
If the former drug company executive is confirmed by the Senate, he would replace Dr. Tom Price, who resigned in September after a scandal involving government travel on private aircraft.
One California university is trying a new strategy to help minority students perform better in STEM classes and develop the mental resilience to face future challenges.
The relationship has been fraught with disputes about which research should be funded. Four House members have asked NFL Commissioner Roger Goodell whether the league plans to honor its commitment.
Three genetic changes could be enough to make a bird flu strain that's already killing some people in China highly contagious. Are experiments with a deliberately mutated version too risky?
Some members of Congress say the U.S. government should use the patent rights it owns for any drugs that were developed with federal grants to drive down the prices of those drugs.
The National Institutes of Health, which funds research in treatments and cures, could lose 20 percent of its budget under the administration's proposal. More money would go for addiction treatment.
Sweeping legislation that would reshape how the Food and Drug Administration reviews new products and bolster National Institutes of Health funding is moving closer to becoming law. What's at stake?
The House could vote Wednesday on a vast bill that stretches nearly a thousand pages and holds changes large and small for the National Institutes of Health and the Food and Drug Administration.
